




RealRate

PHARMACEUTICAL 2015

Northwest Biotherapeutics INC
Rank 246 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 76%, being 178% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	14,642
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	68,880
Liabilities, Non-Current	24,588
Other Assets	3,800
Other Compr. Net Income	0
Other Expenses	19,912
Other Liabilities	0
Other Net Income	-15,039
Other Revenues	1,903
Property and Equipment	39,999
Research and Development	85,637
Selling, General and Administrative Expense	16,949

Output Variable	Value in 1000 USD
Assets	58,441
Liabilities	93,468
Expenses	122,498
Revenues	1,903
Stockholders Equity	-35,027
Net Income	-135,634
Comprehensive Net Income	-135,634
BaseVar	145,674
ECR before LimitedLiability	-279%
Economic Capital Ratio	76%